StatusThe thesis was presented on the 21 December, 2005
Approved by NCAA on the 23 February, 2006
Abstract– 0.40 Mb / in russian
– 0.38 Mb / in romanian
0.83 Mb /
The present study has been based on materials of investigation and observation of 100 patients with rheumatoid arthritis (RA) during 2001-2004 period in order to evaluate the clinic polymorphism traits and their correlation with genetic predisposition suggested by a few molecular markers of malady.
The performed explorations have estimated the presence of a series of molecular markers which can facilitate the genetic risk determination for RA evolution, primary being the interleukine-alpha gene, located on chromosome 2 (2q). Using the primers IL1R1A/ILR1B from structural segment of this gene thereby PCR the DNA patterns of blood of the RA patients on whom 2 alleles were determined: one normal (A) and another mutant (B), their incidence being as: in study group AA – 67,9%, AB – 25,4%, and BB – 6,7%; in control group (healthy) AA – 96,7%; AB – 3,3%, and BB – 0%. The incidence of mutant allele assessment is hence an important goal in examined patients, additionally to note that the disease on RA patients with genotype BB is developing earlier although the presence of allele B in AB and BB genotypes is emphasized as a risk factor for RA patients.
Underlined the role of the mitochondrial DNA repairing process disorder as a
predictor of rheumatoid factor presence, author utilizing a set of mitochondrial DNA
complementary primers mt DNA (forward)/mt DNA (reverse) has determined that
repairing process alteration correlates with the presence of rheumatoid factor in explored
patients. The investigations realized with primers of 3DQBAMP-A and 3DQBAM-O2B
of HLA DQB1 gene have identified a DNA segment of 257 b.p. size and another of 100
b.p. size associated to mutant allele, although the last presence proposes RA development
risks. Author concludes that the use of 3 pares of primers 1R1A/IL1R1B, mt DNA
(forward)/mt DNA (reverse) and 3DQBAMP-A/3DQBAMP-2B – for molecular testing
of DNA can be useful for RA genetic predisposition estimation, and the molecular
markers regarding for this study are feasible for genetic investigation of patients whose
clinical statement may be enclosed for rheumatoid arthritis diagnosis.
Under consideration  :